Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
04 2023
Historique:
received: 08 09 2022
revised: 24 11 2022
accepted: 12 12 2022
pubmed: 1 1 2023
medline: 28 3 2023
entrez: 31 12 2022
Statut: ppublish

Résumé

Constitutional mismatch repair deficiency (CMMRD) is a rare recessive childhood cancer predisposition syndrome caused by germline mismatch repair variants. Constitutional microsatellite instability (cMSI) is a CMMRD diagnostic hallmark and may associate with cancer risk. We quantified cMSI in a large CMMRD patient cohort to explore genotype-phenotype correlations using novel MSI markers selected for instability in blood. Three CMMRD, 1 Lynch syndrome, and 2 control blood samples were genome sequenced to >120× depth. A pilot cohort of 8 CMMRD and 38 control blood samples and a blinded cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplicon sequenced to 5000× depth. Sample cMSI score was calculated using a published method comparing microsatellite reference allele frequencies with 80 controls. Thirty-two mononucleotide repeats were selected from blood genome and pilot amplicon sequencing data. cMSI scoring using these MSI markers achieved 100% sensitivity (95% CI, 93.6%-100.0%) and specificity (95% CI 97.9%-100.0%), was reproducible, and was superior to an established tumor MSI marker panel. Lower cMSI scores were found in patients with CMMRD with MSH6 deficiency and patients with at least 1 mismatch repair missense variant, and patients with biallelic truncating/copy number variants had higher scores. cMSI score did not correlate with age at first tumor. We present an inexpensive and scalable cMSI assay that enhances CMMRD detection relative to existing methods. cMSI score is associated with mismatch repair genotype but not phenotype, suggesting it is not a useful predictor of cancer risk.

Sections du résumé

BACKGROUND & AIMS
Constitutional mismatch repair deficiency (CMMRD) is a rare recessive childhood cancer predisposition syndrome caused by germline mismatch repair variants. Constitutional microsatellite instability (cMSI) is a CMMRD diagnostic hallmark and may associate with cancer risk. We quantified cMSI in a large CMMRD patient cohort to explore genotype-phenotype correlations using novel MSI markers selected for instability in blood.
METHODS
Three CMMRD, 1 Lynch syndrome, and 2 control blood samples were genome sequenced to >120× depth. A pilot cohort of 8 CMMRD and 38 control blood samples and a blinded cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplicon sequenced to 5000× depth. Sample cMSI score was calculated using a published method comparing microsatellite reference allele frequencies with 80 controls.
RESULTS
Thirty-two mononucleotide repeats were selected from blood genome and pilot amplicon sequencing data. cMSI scoring using these MSI markers achieved 100% sensitivity (95% CI, 93.6%-100.0%) and specificity (95% CI 97.9%-100.0%), was reproducible, and was superior to an established tumor MSI marker panel. Lower cMSI scores were found in patients with CMMRD with MSH6 deficiency and patients with at least 1 mismatch repair missense variant, and patients with biallelic truncating/copy number variants had higher scores. cMSI score did not correlate with age at first tumor.
CONCLUSIONS
We present an inexpensive and scalable cMSI assay that enhances CMMRD detection relative to existing methods. cMSI score is associated with mismatch repair genotype but not phenotype, suggesting it is not a useful predictor of cancer risk.

Identifiants

pubmed: 36586540
pii: S0016-5085(22)01444-5
doi: 10.1053/j.gastro.2022.12.017
pii:
doi:

Substances chimiques

Mismatch Repair Endonuclease PMS2 EC 3.6.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

579-592.e8

Subventions

Organisme : Medical Research Council
ID : MC_PC_17168
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1297/A15394
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C569/A24991
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Richard Gallon (R)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. Electronic address: richard.gallon@newcastle.ac.uk.

Rachel Phelps (R)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Christine Hayes (C)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Laurence Brugieres (L)

Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Léa Guerrini-Rousseau (L)

Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Team "Genomics and Oncogenesis of pediatric Brain Tumors," INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Chrystelle Colas (C)

Département de Génétique, Institut Curie, Paris, France; INSERM U830, Université de Paris, Paris, France.

Martine Muleris (M)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Centre de Recherche Saint-Antoine, Paris, France.

Neil A J Ryan (NAJ)

The Academic Women's Health Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Department of Gynaecology Oncology, Royal Infirmary of Edinburgh, Edinburgh, UK.

D Gareth Evans (DG)

Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK.

Hannah Grice (H)

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Emily Jessop (E)

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Annabel Kunzemann-Martinez (A)

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Centre for Inflammation and Tissue Repair, University College London, London, UK.

Lilla Marshall (L)

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Esther Schamschula (E)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

Klaus Oberhuber (K)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

Amedeo A Azizi (AA)

Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.

Hagit Baris Feldman (H)

The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Andreas Beilken (A)

Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

Nina Brauer (N)

Pediatric Oncology, Helios-Klinikum, Krefeld, Germany.

Triantafyllia Brozou (T)

Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.

Karin Dahan (K)

Centre de Génétique Humaine, Institut de Pathologie et Génétique, Gosselies, Belgium.

Ugur Demirsoy (U)

Department of Pediatric Oncology, Kocaeli University, Kocaeli, Turkey.

Benoît Florkin (B)

Department of Pediatrics, Citadelle Hospital, University of Liège, Liège, Belgium.

William Foulkes (W)

Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada; Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Department of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.

Danuta Januszkiewicz-Lewandowska (D)

Department of Pediatric Oncology, Hematology and Transplantation Medical University, Poznan, Poland.

Kristi J Jones (KJ)

Department of Clinical Genetics, Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, New South Wales, Australia; University of Sydney School of Medicine, Sydney, New South Wales, Australia.

Christian P Kratz (CP)

Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

Stephan Lobitz (S)

Gemeinschaftsklinikum Mittelrhein, Department of Pediatric Hematology and Oncology, Koblenz, Germany.

Julia Meade (J)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Michaela Nathrath (M)

Pediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany; Department of Pediatrics, Pediatric Oncology Center, Technische Universität München, Munich, Germany.

Hans-Jürgen Pander (HJ)

Institut für Klinische Genetik, Olgahospital, Stuttgart, Germany.

Claudia Perne (C)

Institute of Human Genetics, Medical Faculty, University of Bonn and National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.

Iman Ragab (I)

Pediatrics Department, Hematology-Oncology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Tim Ripperger (T)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Thorsten Rosenbaum (T)

Department of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany.

Daniel Rueda (D)

Hereditary Cancer Laboratory, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.

Tomasz Sarosiek (T)

Department of Oncology, Luxmed Onkologia, Warsaw, Poland.

Astrid Sehested (A)

Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Isabel Spier (I)

Institute of Human Genetics, Medical Faculty, University of Bonn and National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.

Manon Suerink (M)

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Stefanie-Yvonne Zimmermann (SY)

Department of Pediatric Hematology and Oncology, Children's Hospital, University Hospital, Frankfurt, Germany.

Johannes Zschocke (J)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

Gillian M Borthwick (GM)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Katharina Wimmer (K)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

John Burn (J)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Michael S Jackson (MS)

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Mauro Santibanez-Koref (M)

Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH